aod9604 phase 2 trial results weight loss Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Injection:SubQ Serum b12 injections training How
SKU: 81760295680
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11





















